Literature DB >> 6299184

Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis.

R Latif, A S Dajani.   

Abstract

We evaluated the diffusion of ceftriaxone into the cerebrospinal fluid of 27 infants and children with meningitis who were receiving conventional antimicrobic therapy. Ceftriaxone was administered as a single 75 mg/kg dose and was given early or late or both in the course of the illness. Three hours after a dose, the mean cerebrospinal fluid ceftriaxone level was 5.7 micrograms/ml in patients studied early in the course of meningitis and 2.1 micrograms/ml in patients studied later in the illness. Six hours after a dose, the mean cerebrospinal fluid ceftriaxone levels early and late in meningitis were 7.2 and 2.5 micrograms/ml, respectively. The diffusion did not correlate with the leukocyte count or the protein or glucose content of the cerebrospinal fluid. Serial, simultaneous cerebrospinal fluid and plasma ceftriaxone levels were also determined in three additional patients with ventriculo-peritoneal shunt infections and external ventriculostomy drainage. The cerebrospinal fluid ceftriaxone levels in these patients ranged from 0.7 to 8.3 micrograms/ml. Our data indicate that ceftriaxone diffuses sufficiently and consistently into the cerebrospinal fluid to warrant its assessment in the treatment of meningitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6299184      PMCID: PMC184614          DOI: 10.1128/AAC.23.1.46

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Diffusion of ceftriaxone (Ro 13-9004/001) in the cerebrospinal fluid. Comparison with other beta-lactam antibiotics in dogs with healthy meninges and in dogs with experimental meningitis.

Authors:  B Marchou; M Armengaud
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

2.  Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases.

Authors:  M Cadoz; F Denis; H Félix; I Diop Mar
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

3.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

4.  Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.

Authors:  G H McCracken; J D Nelson; L Grimm
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

5.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

6.  Comparative in-vitro activity and mode of action of ceftriaxone (Ro 13-9904), a new highly potent cephalosporin.

Authors:  M J Hall; D Westmacott; P Wong-Kai-In
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

7.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  7 in total
  18 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis.

Authors:  C P Doit; S P Bonacorsi; A J Fremaux; G Sissia; R Cohen; P L Geslin; E H Bingen
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 3.  Cephalosporins in adult meningitis.

Authors:  T R Beam
Journal:  Bull N Y Acad Med       Date:  1984-05

4.  Effect of inoculum size on Haemophilus influenzae type b susceptibility to new and conventional antibiotics.

Authors:  C Laferriere; M I Marks; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

Review 5.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Authors:  Yanli Zhao; Merit E Cudkowicz; Jeremy M Shefner; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jerold S Harmatz; David Schoenfeld; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2014-05-16       Impact factor: 3.126

Review 7.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

8.  Comparison of ceftriaxone and traditional therapy of bacterial meningitis.

Authors:  B L Congeni
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

Authors:  R Nau; H W Prange; P Muth; G Mahr; S Menck; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.